NEW YORK (GenomeWeb News) – AltheaDx today said that it has formed a partnership with Compendia Bioscience to combine their technologies to create tests that can predict patient outcomes in clinical trials.
The initial product developed under the collaboration is the Breast Cancer Segregation Panel Assay — a real-time, PCR-based panel that has been optimized for analysis of RNA extracted from formalin-fixed, paraffin-embedded tissue. The panel includes 96 genes associated with breast cancer identified through a meta-analysis of cancer genomic data from more than 5,000 clinical samples, said AltheaDx.
Under the collaboration, AltheaDx will process and analyze samples at its San Diego-based CLIA and GLP lab. Compendia will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials.
The firms also said that they plan to develop Segregation Panels for other cancer types, with the launch of a Colorectal Cancer Segregation Panel expected to be launched in 2011.
Further terms of the alliance were not disclosed.